UCB (UCBJF)
(Delayed Data from OTC)
$179.05 USD
0.00 (0.00%)
Updated Sep 16, 2024 12:46 PM ET
1-Strong Buy of 5 1
C Value D Growth F Momentum D VGM
Price, Consensus and EPS Surprise
UCBJF 179.05 0.00(0.00%)
Will UCBJF be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for UCBJF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for UCBJF
Best Momentum Stock to Buy for August 19th
UCBJF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for UCBJF
Biogen, UCB mark late-stage trial win for autoimmune disease therapy
UCB gets expanded FDA approval for psoriasis drug Bimzelx
Barclays Reaffirms Their Buy Rating on UCB SA (0NZT)
Viridian: Active TED Data Signifies Next Round Of Positive Data On The Way
Week In Review: UCB Sells China Drug Portfolio For $680 Million To CBC